Immunotherapy safe in the treatment of patients with cancer who have HIV infection. This is the conclusion reached by researchers from Germany.
Millions of people on our planet have HIV, but normally we live with it for decades due to the use of medications category of antiretroviral therapy. However, what if these patients sick with malignant tumours, which require the use of the most advanced treatments – immunotherapy? It is especially important that HIV the immune system is compromised, which increases the likelihood of developing certain tumors.
Previously, patients with HIV have traditionally been excluded from clinical trials, so it’s not clear how they react to different types of cancer treatment, including immunotherapy. And now at the Congress in Munich, it became known that the use of inhibitors of PD-1 илиPD-L1 is a suitable solution for HIV-infected patients who are faced with cancer. It was about the use of the medication, called nivolumab. The effectiveness of this drug was tested on patients with metastatic melanoma and metastatic non-small cell lung cancer. While most patients HIV viral load was nediagnostirovannoe thanks to the medicine, in two patients it was very low, and one unknown.
All patients were followed for 11 months and by the end of the observation period the average number of injections was 6 nicolumbo. Scientists did not observe any toxic deaths or adverse effects related to the immune system. One of the patients jumped viral load, and decreased number of lymphocytes that talked about the reactivation of viruses, but it happened after he broke antiretroviral therapy. Thus immunotherapy in the treatment of cancer in HIV-infected patients recognized as safe. (READ MORE)